LY 2525623

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameLY 2525623
Drug Alias NameAnti-IL-23 MAb (Eli Lilly)Anti-IL-23 antibody (Eli Lilly)LY-2525623
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInflammation mediators inhibitorsInterleukin-23 inhibitorsT lymphocytes inhibitors
TargetsInterleukin-23
Therapy Area/IndicationsPsoriasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsPsoriasis

Other Information

ATC CodeN/A
Related LinksN/A